Dynamic Regulation Genes at Microtubule Plus Ends: A Novel Class of Glioma Biomarkers
Glioma is the most prevalent and aggressive primary nervous system tumor with an unfavorable prognosis. Microtubule plus-end-related genes (MPERGs) play critical biological roles in the cell cycle, cell movement, ciliogenesis, and neuronal development by coordinating microtubule assembly and dynamics. This research seeks to systematically explore the oncological characteristics of these genes in microtubule-enriched glioma, focusing on developing a novel MPERG-based prognostic signature to improve the prognosis and provide more treatment options for glioma patients. First, we thoroughly analyzed and identified 45 differentially expressed MPERGs in glioma. Based on these genes, glioma patients were well distinguished into two subgroups with survival and tumor microenvironment infiltration differences. Next, we further screened the independent prognostic genes (<i<CTTNBP2</i<, <i<KIF18A</i<, <i<NAV1</i<, <i<SLAIN2</i<, <i<SRCIN1</i<, <i<TRIO</i<, and <i<TTBK2</i<) using 36 prognostic-related differentially expressed MPERGs to construct a signature with risk stratification and prognostic prediction ability. An increased risk score was related to the malignant progression of glioma. Therefore, we also designed a nomogram model containing clinical factors to facilitate the clinical use of the risk signature. The prediction accuracy of the signature and nomogram model was verified using The Cancer Genome Atlas and Chinese Glioma Genome Atlas datasets. Finally, we examined the connection between the signature and tumor microenvironment. The signature positively correlated with tumor microenvironment infiltration, especially immunoinhibitors and the tumor mutation load, and negatively correlated with microsatellite instability and cancer stemness. More importantly, immune checkpoint blockade treatment and drug sensitivity analyses confirmed that this prognostic signature was helpful in anticipating the effect of immunotherapy and chemotherapy. In conclusion, this research is the first study to define and validate an MPERG-based signature closely associated with the tumor microenvironment as a reliable and independent prognostic biomarker to guide personalized choices of immunotherapy and chemotherapy for glioma patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Biology - 12(2023), 3, p 488 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wenwen Wang [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Biology (General) |
|---|
| doi: |
10.3390/biology12030488 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ087431157 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ087431157 | ||
| 003 | DE-627 | ||
| 005 | 20240413052826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230331s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/biology12030488 |2 doi | |
| 035 | |a (DE-627)DOAJ087431157 | ||
| 035 | |a (DE-599)DOAJ923cc2168ed0420187c79c6fe28b0148 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QH301-705.5 | |
| 100 | 0 | |a Wenwen Wang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dynamic Regulation Genes at Microtubule Plus Ends: A Novel Class of Glioma Biomarkers |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Glioma is the most prevalent and aggressive primary nervous system tumor with an unfavorable prognosis. Microtubule plus-end-related genes (MPERGs) play critical biological roles in the cell cycle, cell movement, ciliogenesis, and neuronal development by coordinating microtubule assembly and dynamics. This research seeks to systematically explore the oncological characteristics of these genes in microtubule-enriched glioma, focusing on developing a novel MPERG-based prognostic signature to improve the prognosis and provide more treatment options for glioma patients. First, we thoroughly analyzed and identified 45 differentially expressed MPERGs in glioma. Based on these genes, glioma patients were well distinguished into two subgroups with survival and tumor microenvironment infiltration differences. Next, we further screened the independent prognostic genes (<i<CTTNBP2</i<, <i<KIF18A</i<, <i<NAV1</i<, <i<SLAIN2</i<, <i<SRCIN1</i<, <i<TRIO</i<, and <i<TTBK2</i<) using 36 prognostic-related differentially expressed MPERGs to construct a signature with risk stratification and prognostic prediction ability. An increased risk score was related to the malignant progression of glioma. Therefore, we also designed a nomogram model containing clinical factors to facilitate the clinical use of the risk signature. The prediction accuracy of the signature and nomogram model was verified using The Cancer Genome Atlas and Chinese Glioma Genome Atlas datasets. Finally, we examined the connection between the signature and tumor microenvironment. The signature positively correlated with tumor microenvironment infiltration, especially immunoinhibitors and the tumor mutation load, and negatively correlated with microsatellite instability and cancer stemness. More importantly, immune checkpoint blockade treatment and drug sensitivity analyses confirmed that this prognostic signature was helpful in anticipating the effect of immunotherapy and chemotherapy. In conclusion, this research is the first study to define and validate an MPERG-based signature closely associated with the tumor microenvironment as a reliable and independent prognostic biomarker to guide personalized choices of immunotherapy and chemotherapy for glioma patients. | ||
| 650 | 4 | |a glioma | |
| 650 | 4 | |a microtubule plus-end-related gene | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a tumor microenvironment | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a drug response | |
| 653 | 0 | |a Biology (General) | |
| 700 | 0 | |a Weilong Li |e verfasserin |4 aut | |
| 700 | 0 | |a Lifang Pan |e verfasserin |4 aut | |
| 700 | 0 | |a Lingjie Li |e verfasserin |4 aut | |
| 700 | 0 | |a Yasi Xu |e verfasserin |4 aut | |
| 700 | 0 | |a Yuqing Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Xiaochen Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Shirong Zhang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Biology |d MDPI AG, 2012 |g 12(2023), 3, p 488 |w (DE-627)DOAJ000006890 |x 20797737 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:3, p 488 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/biology12030488 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/923cc2168ed0420187c79c6fe28b0148 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2079-7737/12/3/488 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2079-7737 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 3, p 488 | ||